8-K: Turning Point Brands Reports Strong Q4 and Full Year 2024 Results, Adjusted EBITDA Surges

Turning Point Brands announces a 12.8% increase in Q4 net sales and a 12.0% rise in full-year adjusted EBITDA, driven by growth in the Stokers segment and Modern Oral products.

Summary

• Turning Point Brands (TPB) reported its financial results for the fourth quarter and full year ended December 31, 2024.
• Q4 2024 net sales increased by 12.8% year-over-year to $93.7 million.
• Adjusted EBITDA for Q4 2024 rose by 5.3% to $26.2 million.
• Full-year 2024 net sales increased by 11.0% to $360.7 million.
• Full-year 2024 adjusted EBITDA increased by 12.0% to $104.5 million.
• The company projects full-year 2025 adjusted EBITDA to be between $108 million and $113 million.
• Modern Oral sales are projected to be $60 million to $80 million in 2025.
• Net income decreased 76.1% to $2.4 million in Q4 2024, primarily due to a one-time loss from discontinued operations of $7.3 million.
• Adjusted net income for Q4 2024 increased 12.7% to $18.0 million.
• Diluted EPS for Q4 2024 was $0.13, and adjusted diluted EPS was $0.98.
• Net income increased 3.5% to $39.8 million for the full year 2024.
• Adjusted net income increased 15.5% to $65.9 million for the full year 2024.
• Diluted EPS for the full year 2024 was $2.14, and adjusted diluted EPS was $3.49.
• Total gross debt as of December 31, 2024, was $248.6 million, with net debt at $202.4 million.
• The company had total liquidity of $103.6 million at the end of the quarter.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong growth in key segments and adjusted EBITDA. However, a decrease in net income due to discontinued operations and increased SG&A expenses tempers the overall sentiment.

Positives

• Q4 2024 net sales increased by 12.8% year-over-year to $93.7 million.
• Adjusted EBITDA for Q4 2024 rose by 5.3% to $26.2 million.
• Full-year 2024 net sales increased by 11.0% to $360.7 million.
• Full-year 2024 adjusted EBITDA increased by 12.0% to $104.5 million.
• Stokers Product Segment net sales increased 25.8% in Q4 2024.
• FRE sales in Modern Oral more than quadrupled versus the year-ago quarter and grew 26% sequentially.
• The company is comfortable with its liquidity position and is within its net leverage range of 2 to 3 times.
• The company successfully launched ALP during the quarter.

Negatives

• Net income decreased 76.1% to $2.4 million in Q4 2024, primarily due to a one-time loss from discontinued operations of $7.3 million.
• Zig-Zag Products segment gross profit decreased 2.5% to $24.8 million in Q4 2024.
• Zig-Zag Products segment gross margin declined 240 basis points to 54.1% in Q4 2024, driven primarily by product mix.
• SG&A expenses increased to $34.5 million in Q4 2024 compared to $27.1 million in Q4 2023, including restructuring costs.

Risks

• The company faces risks and uncertainties related to forward-looking statements, including those detailed in its SEC filings.
• The PMTA regime requires the company to submit applications to the FDA to receive marketing authorization to continue to sell certain of its product lines.

Future Outlook

Management expects full-year 2025 adjusted EBITDA to be $108 to $113 million and projects combined Modern Oral sales of $60 to $80 million.

Management Comments

• Graham Purdy, President and CEO, commented, 'We were pleased with our fourth quarter and full year 2024 results and the momentum we are seeing across the organization. We believe Zig-Zag remains on a sustainable growth trajectory with Stokers MST continuing to grow market share.'

Industry Context

The company's focus on alternative smoking accessories and consumables with active ingredients positions it within a growing segment of the consumer products market. The growth in Modern Oral sales reflects a broader trend towards alternative nicotine consumption methods.

Comparison to Industry Standards

• It's difficult to provide a precise comparison without knowing TPB's direct competitors' results for the same period.
• However, the growth in adjusted EBITDA and net sales suggests TPB is performing competitively within its industry segment.
• Companies like Swedish Match (now part of Philip Morris International) and Altria Group (MO) are key players in the broader tobacco and nicotine products market, and TPB's performance can be benchmarked against their growth rates in similar product categories.
• Specifically, the growth in Modern Oral sales can be compared to the performance of similar products offered by these larger companies.

Stakeholder Impact

• Shareholders should be encouraged by the growth in adjusted EBITDA and net sales.
• Employees may benefit from the company's continued growth and success.
• Customers will likely see continued investment in product innovation and availability.
• Suppliers can expect continued demand for raw materials and components.
• Creditors should be reassured by the company's strong liquidity position and debt management.

Next Steps

• The company will hold a conference call on March 6, 2025, to review the financial results.
• Management will focus on achieving the 2025 adjusted EBITDA and Modern Oral sales guidance.

Key Dates